GlassScriptPhysician profile
Andres David Darquea
NPI 1891215679
$947.92
in general payments reported to CMS, 2019-2025
17 companies · $196 in 2025
The $196 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.80 · 2023: $578 · 2024: $161 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $919 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $918.85 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $330.89 | 2023 | Myrisk |
| Novartis Pharmaceuticals Corporation | $136.60 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $84.15 | 2023-2025 | Keytruda, Welireg |
| Sobi, INC | $54.98 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $49.09 | 2024-2025 | Imfinzi, Tagrisso, Enhertu |
| Alexion Pharmaceuticals, INC. | $48.58 | 2024 | Ultomiris |
| Abbott Laboratories | $46.55 | 2023 | Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $34.63 | 2025 | Inspire |
| Daiichi Sankyo INC. | $30.54 | 2022-2023 | Enhertu |
| Insulet Corporation | $21.65 | 2023 | Omnipod |
| Karyopharm Therapeutics INC. | $18.74 | 2023 | Xpovio |
| Eisai INC. | $17.81 | 2024 | |
| Novo Nordisk INC | $16.27 | 2025 | Ozempic |
| Axonics, INC. | $15.30 | 2023 | Axonics |
| Coherus Oncology, INC. | $15.00 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $13.68 | 2024 | Zoladex |
| Spectrum Pharmaceuticals INC. | $13.46 | 2023 | Rolvedon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andres Darquea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.